20 Mar Atopic Dermatitis: Dupilumab Can Rapidly Improve Itch in Moderate to Severe Eczema
MedicalResearch.com Interview with:
Dr. Yosipovitch
Gil Yosipovitch, MD, Professor
Miami Itch Center
Lennar Medical Foundation
South Miami Clinic in Coral Gables
University of Miami Health System
MedicalResearch.com: What is the background for this study? How does Dupilumab (Dupixent) differ from other medications for atopic dermatitis/eczema?
Response: Atopic dermatitis (AD) is characterized by intense itch (pruritus) that is one of the most burdensome symptoms; therefore, rapid and sustained improvement in itch is an important marker of treatment benefit. Dupixent® (dupilumab) is approved in the U.S. for adults and adolescents with inadequately-controlled moderate-to-severe Atopic Dermatitis.
Dupilumab remains the first and only biologic medicine for uncontrolled moderate-to-severe atopic dermatitis. Dupilumab is the first and only fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from dupilumab clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.
MedicalResearch.com: What are the main findings?
Response: Dupilumab treatment demonstrated rapid improvement in itch in adult and adolescent patients with moderate-to-severe Atopic Dermatitis. Dupilumab was also generally well-tolerated with an acceptable safety profile.
Full results of rapid and sustained improvements in itch with dupilumab treatment from four Phase 3 trials with dupilumab in adults and adolescents with moderate-to-severe AD were recently published online in the Journal of the American Academy of Dermatology and available at: https://urldefense.proofpoint.com/v2/url?u=https-3A__www.jaad.org_article_S0190-2D9622-2820-2930305-2D4_fulltext&d=DwIGaQ&c=Dbf9zoswcQ-CRvvI7VX5j3HvibIuT3ZiarcKl5qtMPo&r=zx6i_bQM5Ja1G2nlZhcdgWskM3TYL9VgPbVi0-TRwDQ&m=MZWOSZLvqnINFnrl_YtEOFI2F4hlx2Jz-KkXrozslSo&s=FSccaqwy5V0qBUyuV2mZbjvDb7_W9FuYJOAe5mdxaO8&e=
MedicalResearch.com: What should readers take away from your report?
Response: Dupilumab treatment can improve symptoms after the first dose in some adult and adolescent patients with moderate-to-severe Atopic Dermatitis.
MedicalResearch.com: What recommendations do you have for future research as a result of this work?
Response: Future research assessing whether dupilumab could reduce itch associated with other skin conditions such as severe hand eczema, prurigo nodularis, and itch amongst elderly patients associated with immunosenescence.
MedicalResearch.com: Is there anything else you would like to add?
Response: The rapid response on itch precedes the effect on the atopic rash in both adults and adolescents, as itch is a key driver of the disease. It’s important to address this question and document it during an intake.
Disclosure: Yosipovitch G: Eli Lilly, Pfizer Galderma, Menlo Therapeutics, Novartis, Regeneron Pharmaceuticals, Inc., Sanofi, Trevi Therapeutics, Bellus, Kiniksa− advisory board member; Kiniksa, LEO Pharma, Pfizer, Sun − grants/research funding.
Citation:
Dupilumab Treatment Results in Rapid Improvement in Itch in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (LIBERTY AD SOLO 1 & 2, and ADOL trials)
Yosipovitch, Gil et al.
Journal of Allergy and Clinical Immunology, Volume 145, Issue 2, AB190
[subscribe]
[last-modified]
The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on March 20, 2020 by Marie Benz MD FAAD